We are live on ! Find out more
SCM

Sio Capital Management Portfolio holdings

AUM $697M
1-Year Est. Return 79.73%
This Fund
S&P 500
This Quarter Est. Return
-9.83%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$370M
AUM Growth
+$33.7M
Cap. Flow
+$6.99M
Cap. Flow %
1.89%
Top 10 Hldgs %
68.63%
Holding
64
New
13
Increased
12
Reduced
8
Closed
16

Top Buys

Rank Stock Value
1
TFX icon
Teleflex
TFX
+$16.2M
2
SNN icon
Smith & Nephew
SNN
+$14.5M
3
VXRT
Vaxart
VXRT
+$12.3M
4
ZBH icon
Zimmer Biomet
ZBH
+$9.56M
5
ABT icon
Abbott
ABT
+$9.49M

Top Sells

Rank Stock Value
1
GMED icon
Globus Medical
GMED
+$21.1M
2
CI icon
Cigna
CI
+$17M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$13.6M
4
MDT icon
Medtronic
MDT
+$9.15M
5
EMBC icon
Embecta
EMBC
+$7.77M

Sector Composition

Rank Sector Weight
1 Healthcare 69.35%
2 Consumer Staples 2.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MODD icon
26
Modular Medical
MODD
$12.9M
$2.43M 0.66%
51,312
– –
STOK icon
27
Stoke Therapeutics
STOK
$1.8B
$2.37M 0.64%
175,301
-50,195
-22% -$678K
ENTA icon
28
Enanta Pharmaceuticals
ENTA
$366M
$2.3M 0.62%
177,004
– –
THRD
29
DELISTED
Third Harmonic Bio
THRD
$2.12M 0.57%
163,363
– –
NUVB icon
30
Nuvation Bio
NUVB
$2.2B
$1.95M 0.53%
668,115
-668,116
-50% -$2.04M
SPRY icon
31
ARS Pharmaceuticals
SPRY
$509M
$1.85M 0.5%
217,864
-318,299
-59% -$2.82M
VTYX
32
DELISTED
Ventyx Biosciences
VTYX
$1.8M 0.49%
778,924
+400,924
+106% +$1.67M
CMPS
33
Compass Pathways
CMPS
$1.53B
$1.77M 0.48%
+293,417
New +$2.31M
ARQT icon
34
Arcutis Biotherapeutics
ARQT
$3.36B
$1.48M 0.4%
159,626
-476,343
-75% -$4.31M
XFOR icon
35
X4 Pharmaceuticals
XFOR
$375M
$1.45M 0.39%
83,327
-36,287
-30% -$1.19M
PRLD icon
36
Prelude Therapeutics
PRLD
$366M
$1.22M 0.33%
320,394
– –
APRE icon
37
Aprea Therapeutics
APRE
$7.68M
$1.13M 0.3%
276,603
– –
RAPT
38
DELISTED
RAPT Therapeutics
RAPT
$961K 0.26%
39,375
– –
AVTX icon
39
Avalo Therapeutics
AVTX
$965M
$891K 0.24%
71,458
+61,307
+604% +$795K
FHTX icon
40
Foghorn Therapeutics
FHTX
$266M
$700K 0.19%
121,672
– –
BOLD
41
Boundless Bio
BOLD
$56.2M
$627K 0.17%
162,058
+19,058
+13% +$182K
VSTM icon
42
Verastem
VSTM
$510M
$398K 0.11%
+133,412
New +$1.1M
NYXH
43
Nyxoah
NYXH
$140M
$354K 0.1%
50,839
– –
NXTC icon
44
NextCure
NXTC
$16.8M
$207K 0.06%
10,833
– –
ASLN
45
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$76.2K 0.02%
31,769
– –
HUMAW icon
46
Humacyte Inc Warrant
HUMAW
$1.55M
$70.5K 0.02%
49,998
– –
RCKTW icon
47
Rocket Pharmaceuticals Warrant
RCKTW
$149K
$28.9K 0.01%
400,000
– –
CMAXW
48
DELISTED
CareMax, Inc. Warrant
CMAXW
$200 ﹤0.01%
12,808
– –
CTMX icon
49
CytomX Therapeutics
CTMX
$675M
– –
-1,598,590
Closed -$3.48M
EMBC icon
50
Embecta
EMBC
$216M
– –
-585,418
Closed -$7.77M
1
2
3

Similar funds

GUB
Golden Unicorn BVI Road Town $697M AUM 55.92% 1-Year Est. Return
KLI
Kelman-Lazarov Inc Memphis, Tennessee $698M AUM 14.07% 1-Year Est. Return
JA
JLB & Associates Plymouth, Michigan $696M AUM 17.86% 1-Year Est. Return
WIC
Wilkins Investment Counsel Boston, Massachusetts $698M AUM 17.36% 1-Year Est. Return
AAM
Auxier Asset Management Aurora, Oregon $696M AUM 18.07% 1-Year Est. Return
TCM
Tensile Capital Management Larkspur, California $698M AUM 2.4% 1-Year Est. Return
CA
Calton & Associates Tampa, Florida $696M AUM 18.3% 1-Year Est. Return
SAM
Silverback Asset Management Chapel Hill, North Carolina $699M AUM 72.42% 1-Year Est. Return

Sio Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Sio Capital Management held 64 positions worth $370M, up 10% from $336M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Sio Capital Management's Q2 2024 filing shows 13 new, 12 increased, 8 reduced and 16 closed positions. Its largest new stake was Smith & Nephew: 579,619 shares worth $14.4M. The largest sale was Globus Medical, an estimated $21.1M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 85% a quarter earlier, followed by Consumer Staples.

  • Sio Capital Management's largest Q2 2024 buy was Smith & Nephew: 579,619 shares worth $14.4M.
  • Sio Capital Management added most to Teleflex in Q2 2024, an estimated $16.2M increase.
  • Sio Capital Management's biggest Q2 2024 reduction was Cigna, cutting an estimated $17M.
  • Sio Capital Management fully exited Globus Medical in Q2 2024, selling an estimated $21.1M.
  • Sio Capital Management's ten largest holdings make up 69% of its $370M portfolio in Q2 2024.
  • Sio Capital Management opened 13 new positions and closed 16 in Q2 2024.
  • Sio Capital Management's portfolio value rose 10% quarter-over-quarter to $370M.

Based on Sio Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.